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The quantitation of artemether in both pharmaceutical raw material and injections was carried out by 
high performance liquid chromatography (HPLC) with ultraviolet detection. A Zorbax C
18
 column 
(150 x 4.6 mm; 5 µm), at 30 °C, and a mobile phase composed of acetonitrile and water (70:30), at a flow 
rate of 1ml/min, were used. The detection wavelength was 216 nm and the injection volume was 20 µL. 
The method proved to be linear (r2=0.9999), precise (RSD < 20% for intra-day and inter-day precision), 
accurate and selective regarding possible impurities and excipients of the samples. The detection and 
quantitation limits were 8 μg/mL and 25 μg/mL, respectively. The artemether content obtained in the 
raw material analysis was 99.26% and in the injections, 102.08%. The optimized and validated method 
may be successfully employed to perform routine quality control analyses.
Uniterms: Artemether/quantitation. High performance liquid chromatography/quantitative analysis. 
Antimalarials.
A quantificação de artemeter em matéria-prima farmacêutica e solução injetável foi realizada por 
cromatografia líquida de alta eficiência (CLAE) com detecção na região do ultravioleta. Empregou-se 
coluna Zorbax C
18
 (150 x 4.6 mm; 5 µm), mantida a 30 °C, e fase móvel composta por acetonitrila e água 
(70:30), com fluxo de 1 ml/min. A detecção foi realizada a 216 nm, e o volume de injeção foi 20 µl. O 
método se mostrou linear (r2=0,9999), preciso (DPR < 2,0% para precisão intra-dia e inter-dias) e seletivo 
em relação a possíveis impurezas e excipientes das amostras. Os limites de detecção e quantificação 
obtidos foram 8 μg/mL e 25 μg/mL, respectivamente. O teor médio de artemeter obtido na análise da 
matéria-prima farmacêutica foi 99,26% e na solução injetável, 102,08%. O método otimizado e validado 
pode ser utilizado com sucesso para análises rotineiras em controle de qualidade.
Unitermos: Artemeter/quantificação. Cromatografia líquida de alta eficiência/análise quantitativa. 
Antimaláricos.
INTRODUCTION
Malaria is the world’s most important parasitic in-
fection and effective control of this disease poses a great 
challenge to the public health sector in poor countries 
(Guerin et al., 2002). The incidence of malaria worldwide 
is estimated to be 300-500 million clinical cases each year, 
with around 90% of these occurring in Africa, mostly cau-
sed by Plasmodium falciparum. Malaria is thought to kill 
between 1.1 and 2.7 million people worldwide each year, 
about one million of whom are African children under the 
age of five (World, 2000). Due to the widespread P. falci-
parum resistance to conventional antimalarial drugs, many 
countries have been facing difficulties in effective malaria 
control and treatment. Currently, there are reported cases 
of resistance to all classes of antimalarials, except to arte-
misinin and its derivatives (Wongsrichanalai et al., 2002).
Artemether, also called dihydroartemisinin methyl 
ether (Figure 1), is a synthetic derivative of artemisinin, wi-
dely used in malaria treatment in endemic areas. This drug 
can be administered as an oily solution by intramuscular 
injection, or in tablets orally (Karbwang et al., 1997). In 
addition, artemether can be associated with lumefantrine, 
in fixed-dose combination tablets containing 20 mg of arte-
mether and 120 mg of lumefantrine, as a first-line therapy in 
the treatment of falciparum malaria in Brazil (Brasil, 2006).
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In spite of increasing artemether use in treating mala-
ria within endemic areas, the scientific literature is still limi-
ted regarding analytical methods aimed at quantitation of the 
drug in pharmaceutical products, and in quality evaluations 
of the available formulas. The International Pharmacopeia 
(2006) presents monographs of artemether raw material 
and injection forms. The assay methods of these products 
are high performance liquid chromatography (HPLC) with 
ultraviolet detection (216 nm), and an alternative method in 
which artemether is submitted to acid hydrolysis, followed 
by detection in UV spectrophotometer, at 254 nm. 
The quantitation of artemether in pharmaceutical 
products was described by Atemnkeng et al. (2007a), who 
performed the determination of artemisinin derivatives in 
medicines used in Kenya and Congo, while in a second 
study, Atemnkeng et al. (2007b) quantified artemether, 
methylparaben and propylparaben in a dry suspension 
pediatric formulation. César et al. (2008) carried out the 
simultaneous quantitation of artemether and lumefantrine 
in fixed-dose combination tablets. Each of these studies 
employed high performance liquid chromatography with 
ultraviolet detection in the artemether quantitation. There 
are no currently available studies on the quantitative deter-
mination of artemether in pharmaceutical raw material or 
in injections, employed in the treatment of malaria patients 
in Brazil.
Therefore, the aim of the present work was the quan-
tification of artemether in pharmaceutical raw material and 
injection forms. The method described in the International 
Pharmacopeia (4 ed.) was adapted for the analysis, and the 
parameters of linearity, intra-day precision, inter-day preci-
sion, accuracy and selectivity were validated. The optimized 
method was employed to evaluate the quality of the arteme-
ther injections currently used for treating malaria in Brazil.
MATERIAL AND METHODS
Reagents and material
Artemether chemical reference substance (batch 
10203215, purity 100.0%) and raw material (batch 061010-
4087ER) were purchased from Dafra Pharma (Turnhout, 
Belgium). Samples of artemether injection (80 mg/mL – 
Cipla, batch ZD6375) were kindly donated by the Brazilian 
Health Ministry. Acetonitrile (HPLC grade) and isopropyl 
alcohol, acetone, chloroform and ether (analytical grade) 
were purchased from Tedia (Fairfield, OH, USA). Water 
was purified using a Millipore system (Bedford, MA, USA).
Chromatographic conditions
The HPLC analyses were carried out on an Agilent 
1200 system (Palo Alto, CA, USA), composed of quater-
nary pump, autosampler, diode array detector (DAD) and 
HP ChemStation software. The column used was a Zorbax 
C
18
 (150 x 4.6 mm i.d.; 5 µm particle size) from Agilent, 
maintained at 30 °C. The mobile phase consisted of ace-
tonitrile and water, at a flow rate of 1ml/min. Different 
proportions of these solvents were evaluated, aiming to 
optimize the retention time and peak symmetry. The op-
timized mobile phase was composed of 70% acetonitrile 
and 30% water. The detection was performed at 216 nm 
and the injection volume was 20 µL.
Preparation of standard and sample solutions of 
artemether
Standard solution: Approximately 20 mg of arteme-
ther reference standard was accurately weighed, transfer-
red to a 5 mL volumetric flask and diluted in mobile phase 
(acetonitrile:water – 70:30). The volume was adjusted 
with a mobile phase to a final concentration of 4 mg/mL.
Sample solution of raw material: Approximately 
100 mg of artemether raw material, previously dried at 
60 °C in a vacuum oven for three hours, were accurately 
weighed, transferred to a 25 mL volumetric flask and 
diluted in the mobile phase (acetonitrile:water – 70:30). 
The volume was adjusted with mobile phase to a final 
concentration of 4 mg/mL.
Sample solution of injection form: An aliquot of 
5 mL of the artemether injection was transferred to a 
100 mL volumetric flask. Several solvents were evalua-
ted for miscibility with the injection, and the mixture of 
isopropyl alcohol and acetonitrile (75:25) proved to be 
an adequate dilution. The volume was adjusted with this 
solvent to a final concentration of 4 mg/mL.
Validation
After optimization of the chromatographic con-
ditions, the parameters of linearity, intra-day precision, 
FIGURE 1 – Chemical structure of artemether.
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inter-day precision, accuracy, selectivity, limit of detec-
tion and limit of quantitation were evaluated to validate 
the process, according to the specifications described in 
ANVISA Resolution RDC No. 899 (Brasil, 2003). 
Linearity
Artemether stock solutions, at 8 mg/mL, were 
prepared in acetonitrile, in triplicate. Aliquots of these 
solutions were diluted in the mobile phase to five different 
concentrations. The evaluated linear range was from 50 to 
150% of the test concentration, which corresponds to the 
concentration range from 2 to 6 mg/mL of artemether. The 
analytical curve with peak area versus artemether concen-
tration was plotted and the obtained data were subjected 
to regression analysis.
Precision
The intra-day precision was evaluated by means of 
six determinations at 100% of test concentration (4mg/
ml), for both the raw material and injections. Artemether 
sample solutions were prepared as previously described. 
To evaluate the inter-day precision, the same procedure 
was adopted, performing the analyses over two conse-
cutive days. In each analysis, the artemether content and 
the relative standard deviation (RSD) were calculated.
Accuracy
The accuracy was evaluated by the standard addition 
method and known amounts of the reference standard were 
added to the artemether injection. Artemether standard 
solutions, at three different concentrations, were added 
to the injection to give final concentrations of 3 mg/mL, 
4 mg/mL and 5 mg/mL, corresponding to 75%, 100% 
and 125% of the test concentration, respectively. At each 
concentration, the solutions were prepared in triplicate and 
the recovery was calculated.
Selectivity
The selectivity of the chromatographic method was 
determined by evaluation of the spectral purity of the arte-
mether peaks obtained in chromatograms of both standard 
and sample solutions. This test was performed by means of 
overlapping ultraviolet spectra obtained at different points 
of the chromatographic peak, in order to verify whether 
other substances co-eluted at the same retention time of 
the artemether peak.
Limits of detection (LOD) and quantitation (LOQ)
These limits were calculated using the analytical 
curve parameters (standard deviation of intercept and 
slope), according to the equations described in Resolution 
RDC No. 899 (Brasil, 2003).
Analyses of artemether raw material and injection
Samples of artemether raw material and injection 
were analyzed using the optimized and validated HPLC 
method. The solutions for analysis were prepared follo-
wing the previously described procedure. The artemether 
mean content and relative standard deviation (RSD) were 
determined in each analyzed sample.
RESULTS AND DISCUSSION
Initially, the artemether spectrum in the ultraviolet 
region was obtained in the range of 200 to 400 nm using 
FIGURE 2 – Ultraviolet spectrum obtained at DAD, using an artemether solution at 4 mg/mL in mobile phase, injection volume 
of 20 μL.
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the diode array detector (DAD) of the chromatograph 
with a solution at 4 mg/mL in the mobile phase. The 
maximum absorption wavelengths were verified, as well 
as the artemether absorptivity in the ultraviolet region 
(Figure 2).
According to the obtained spectrum, artemether 
absorbs only in the initial ultraviolet region. Thus, the 
artemether detection is possible at 216 nm. However, 
considering its low molar absorptivity, the concen-
tration of the solutions used in the analyses must be 
considerably high. Following the procedure described 
in International Pharmacopeia (4 ed.), it is necessary to 
use standard and sample solutions containing 10 mg/
mL of artemether. In this study, the artemether concen-
tration used was 4 mg/mL. At this concentration, the 
artemether peak presents the adequate intensity required 
for integration and quantitation, while reducing the 
consumption of artemether reference standard for the 
preparation of the solution.
Some adaptations in the chromatographic conditions 
described in International Pharmacopeia were carried out 
for the quantitation of artemether in the raw material and 
injection. In the pharmacopeia procedure, the length of 
the chromatographic column should be 250 mm with an 
acetonitrile concentration of 62% in the mobile phase. For 
the purpose of reducing the analyses time, and to improve 
the peak symmetry, the column length was reduced to 
150 mm and the acetonitrile concentration was increased 
to 70%. Under these conditions, it was possible to obtain a 
symmetric peak, with a tailing factor of 1.25 and retention 
time of 6.70 minutes (Figure 3).
Some problems regarding the preparation of the 
injection sample solution were experienced. According 
to the procedure described in International Pharmacopeia 
(2006), the injection should be quantitatively diluted in the 
mobile phase, resulting in a diluted solution at the desired 
concentration. However, since the artemether injection is 
highly oily and immiscible with the mobile phase and with 
pure acetonitrile, the execution of this procedure resulted 
in the separation of the solution in two phases. The mis-
cibility of the artemether injection with several solvents 
was then evaluated, and it was verified that the injection 
was miscible only with organic solvents, such as acetone, 
chloroform, ether or isopropyl alcohol.
As isopropyl alcohol also showed adequate misci-
bility with the employed mobile phase, this solvent was 
selected for the dilution. The proportion of isopropyl alco-
hol in acetonitrile was evaluated, and a diluent constituted 
of 75% isopropyl alcohol and 25% acetonitrile proved to 
be adequate for the dilution of the injection, and for the 
subsequent analyses in the chromatograph.
Validation
Linearity
The resulting analytical curve indicated an ade-
quate linear correlation between the artemether con-
centrations and the peak areas, in the range of 2 to 
6 mg/mL. Data from the regression analysis are demons-
trated in Table I. The regression coefficient (r2 = 0.9999) 
indicated that, in the evaluated concentration range, the 
peak areas were directly proportional to the artemether 
concentrations and, thus, the method presented adequate 
linearity. The RSD value lower than 2.0% demonstrated 
the precision of the analytical curve.
Precision
The intra-day precision of the HPLC method was 
evaluated by means of six determinations at 100% of the 
test concentration (4mg/ml). In the analyses of artemether 
in the raw material, the RSD values for intra-day (n=6) 
and inter-days (n=12) precision were 0.49% and 0.48%, 
respectively. For the injection, the values were 1.31% and 
0.89% for the intra-day and inter-days precision, respecti-
vely. Thus, precision was demonstrated for both samples, 
since all the obtained RSD values were lower than 2.0%.
Accuracy: Accuracy was evaluated by the stan-
dard addition method, at three different concentrations. 
The recovery obtained at concentrations of 3 mg/mL, 
4 mg/mL and 5 mg/mL were 100.17%, 99.59% and 
100.90%, respectively. The mean recovery was 100.22%, 
proving the accuracy of the HPLC method.
Selectivity
The determination of the spectral purity of the arte-
mether chromatographic peaks was performed in the DAD 
detector. The peak purities obtained from solutions of arte-
mether standard, raw material and injection were 99.95%, 
99.99% and 99.93%, respectively. The high peak purity 
values suggest that other substances did not co-elute with 
the artemether peak, and that the method is selective for the 
quantitation of artemether in raw material and injection.
TABLE I – Results of the regression analyses obtained for the 
HPLC method of artemether quantitation
Regression parameters Results
Regression coefficient (r2) 0.9999
Slope ± standard deviation 32237 ± 26
Intercept ± standard deviation 6.89 ± 2.780
Relative standard deviation (%) 0.06
Concentration range (mg/mL) 2 – 6
Number of points 5
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Limits of detection (LOD) and quantitation (LOQ)
The determination of these limits was carried out 
using an equation that considers the parameters of the 
analytical curve. The resulting LOD and LOQ values were 
8 µg/mL and 25 µg/mL, respectively. Due to the low ab-
sorptivity of artemether in the ultraviolet region, the LOD 
and LOQ were relatively high, however, these values are 
sufficient for the quantitation of the artemether solutions 
in the test concentration used in this study.
The results obtained in the validation process of the 
HPLC method are summarized in Table II. 
Analyses of artemether raw material and injection
The optimized and validated method was applied 
to the quantitation of artemether in pharmaceutical raw 
material and injection. The mean content of the analyzed 
TABLE II – Results of the validation process of the HPLC method 
for artemether quantitation
Validation parameters Results
Intra-day precision
    Raw material – RSD 
    Injection – RSD
0.49 %
1.31 %
Inter-days precision
    Raw material – RSD 
    Injection – RSD
0.48 %
0.89 %
Accuracy
    Mean recovery 100.22%
Selectivity – peak spectral purity
    Standard
    Raw material
    Injection
99.95 %
99.99 %
99.93 %
Limit of detection 8 µg/mL
Limit of quantitation 25 µg/mL
FIGURE 3 – HPLC chromatograms obtained in a Zorbax C
18
 (150 x 4.6 mm, 5 µm) column, at 30 °C, mobile phase composed of 
acetonitrile and water (70:30), flow rate of 1mL/min and detection at 216 nm. Samples of artemether: (A) raw material; (B) injection.
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raw material was 99.26%, while for the injection, the 
content was 102.08%. The chromatograms obtained in the 
analyses of the raw material and injections are demons-
trated in Figure 3.
In both chromatograms, the artemether peak was 
eluted at 6.70 minutes. For the injection, two other peaks 
are evident in the chromatogram. The first peak at 3.15 mi-
nutes is probably related to the oil or other excipients of the 
formulation. The second peak at 3.90 minutes corresponds 
to the isopropyl alcohol used in the sample preparation. 
The identity of the peaks was confirmed by the ultraviolet 
spectra obtained from the DAD. In each analysis, a chro-
matographic resolution between the peaks of artemether 
and isopropyl alcohol, or excipients, was achieved.
CONCLUSION
The optimized and validated HPLC method was 
shown to be adequate for the quantitation and quality eva-
luation of artemether in both pharmaceutical raw material 
and injections, and can be successfully used for routine 
quality control analyses. Considering the increasing use 
of artemether to treat malaria in endemic areas, the avai-
lability of simple and rapid analytical methods is essential 
to evaluate the quality of formulas being used currently.
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